Cite
APA Citation
Merino, M., Kasamon, Y., Li, H., Ma, L., Leong, R., Zhou, J., Reaman, G., Chambers, W., Richardson, N., Theoret, M., Pazdur, R., & Gormley, N. (2022). fDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. Pediatric blood & cancer, 69(8), n/a. http://access.bl.uk/ark:/81055/vdc_100158020481.0x000024